Abstract
The FDA expanded the indication for nilotinib for the treatment of children with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase who are at least a year old, as well as those who are resistant to or cannot tolerate imatinib. The drug is the third tyrosine kinase inhibitor approved for children with this rare cancer.
- ©2018 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Published OnlineFirst April 11, 2018
doi: 10.1158/2159-8290.CD-NB2018-045
FDA Expands Indication for Nilotinib
Jump to section
Advertisement